Aduro BioTech Inc (NASDAQ:ADRO) traded up 7.1% during mid-day trading on Friday . The company traded as high as $1.39 and last traded at $1.36, 549,130 shares changed hands during trading. A decline of 3% from the average session volume of 567,380 shares. The stock had previously closed at $1.27.
A number of equities research analysts recently commented on the stock. CIBC raised shares of Centerra Gold from a “neutral” rating to an “outperform” rating and increased their target price for the company from C$9.00 to C$10.50 in a research report on Monday, June 3rd. Zacks Investment Research cut shares of GENEL ENERGY PL/ADR from a “buy” rating to a “hold” rating in a research report on Tuesday, May 7th. Leerink Swann assumed coverage on shares of Aduro BioTech in a research report on Monday, April 15th. They set an “outperform” rating for the company. Svb Leerink assumed coverage on shares of Tocagen in a research report on Monday, April 15th. They set a “market perform” rating and a $11.00 target price for the company. Finally, ValuEngine cut shares of Zosano Pharma from a “buy” rating to a “hold” rating in a research report on Wednesday, May 1st. Two analysts have rated the stock with a sell rating, four have given a hold rating and six have assigned a buy rating to the stock. The company presently has an average rating of “Hold” and an average price target of $7.68.
The company has a fifty day simple moving average of $1.63. The company has a market capitalization of $105.66 million, a price-to-earnings ratio of -1.17 and a beta of 1.49. The company has a current ratio of 9.11, a quick ratio of 9.11 and a debt-to-equity ratio of 0.29.
Aduro BioTech (NASDAQ:ADRO) last posted its quarterly earnings results on Tuesday, May 7th. The biotechnology company reported ($0.29) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.19) by ($0.10). The company had revenue of $3.94 million during the quarter, compared to analysts’ expectations of $8.08 million. Aduro BioTech had a negative return on equity of 63.81% and a negative net margin of 784.73%. On average, equities research analysts expect that Aduro BioTech Inc will post -0.92 earnings per share for the current year.
In other news, CFO Jennifer Lew sold 18,602 shares of the stock in a transaction on Wednesday, May 1st. The shares were sold at an average price of $4.20, for a total value of $78,128.40. Following the sale, the chief financial officer now owns 139,381 shares in the company, valued at $585,400.20. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 5.20% of the stock is owned by corporate insiders.
Several large investors have recently added to or reduced their stakes in the company. BNP Paribas Arbitrage SA grew its position in shares of Aduro BioTech by 2,060.2% in the first quarter. BNP Paribas Arbitrage SA now owns 13,631 shares of the biotechnology company’s stock valued at $54,000 after purchasing an additional 13,000 shares during the period. Algert Global LLC acquired a new stake in shares of Aduro BioTech in the first quarter valued at about $77,000. Jane Street Group LLC acquired a new stake in shares of Aduro BioTech in the fourth quarter valued at about $59,000. SG Americas Securities LLC grew its position in shares of Aduro BioTech by 45.8% in the first quarter. SG Americas Securities LLC now owns 23,200 shares of the biotechnology company’s stock valued at $92,000 after purchasing an additional 7,283 shares during the period. Finally, Metropolitan Life Insurance Co NY acquired a new stake in shares of Aduro BioTech in the first quarter valued at about $99,000. Hedge funds and other institutional investors own 41.97% of the company’s stock.
About Aduro BioTech (NASDAQ:ADRO)
Aduro BioTech, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies to harness the body's natural immune system for the treatment of patients with challenging diseases. The company is developing ADU-S100, which is in Phase I dose escalation and dose expansion clinical trial and Phase Ib dose escalation and dose expansion clinical trial in combination with spartalizumab to treat patients with advanced, metastatic treatment-refractory solid tumors; Phase I clinical trial in combination with ipilimumab for the treatment of relapsed and refractory melanoma; and Phase Ib/II clinical trial in combination with an approved anti-PD-1 antibody in patients with squamous cell carcinoma of the head and neck.
Further Reading: Golden Cross
Receive News & Ratings for Aduro BioTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aduro BioTech and related companies with MarketBeat.com's FREE daily email newsletter.